The semaglutide impurity des-20-3-γ-Glu-SMT is a structural defect produced during the synthesis or degradation of semaglutide. Semaglutide is a long-acting GLP-1 receptor agonist used to treat type 2 diabetes and obesity. The impurity is characterized by the absence of a key γ-glutamyl (γ-Glu) modification group at position 20. This structural change may affect the biological activity, stability and pharmacokinetic properties of the drug. During drug production and quality control, strict monitoring of such impurities is essential to ensure the safety and efficacy of the drug.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys(AEEA-AEEA-Octadecanedioic Acid)-Ile-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYLEGQAK(AEEA-AEEA-Octadecanedioic Acid)ITWLVLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C185H290N49O57S |
Molecular weight |
4062.17 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |